Bluebird Bio Recieves Receipt Of Delinquency Notice From Nasdaq; The Notices Have No Immediate Effect On The Listing Or Trading Of The Company's Common Stock On The Nasdaq.
Bluebird Bio Recieves Receipt Of Delinquency Notice From Nasdaq; The Notices Have No Immediate Effect On The Listing Or Trading Of The Company's Common Stock On The Nasdaq.
bluebird bio, Inc. (NASDAQ:BLUE) today announced that it received notices (the "notices") on August 20, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").
納斯達克(NASDAQ:BLUE)今天宣佈，自2024年8月20日以來，納斯達克證券交易所(Nasdaq)向該公司發出通知，稱該公司尚未提交截至2024年3月31日的季度報告(2024年一季度10-Q表) 以及截至2024年6月30日的季度報告(2024年二季度10-Q表)， 因此不符合納斯達克交易所規則5250(c)(1)的要求。 該規則要求上市公司及時提交所有必要的定期財務報告給美國證券交易委員會(SEC)。
The notices have no immediate effect on the listing or trading of the Company's common stock on the Nasdaq.
這些通知對公司股票在納斯達克的上市交易沒有直接影響。
譯文內容由第三人軟體翻譯。